Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

04:13 mins

Thomas Brunner, Glaucoma Research Foundation: Presidential Update 2022 Part 1

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Aug 8th 2022

It is estimated that, by 2040, 111 million people around the world will have glaucoma. The Glaucoma Research Foundation is a national non-profit organization dedicated to finding a cure for glaucoma. Founded in 1978 in San Francisco, it funds glaucoma research worldwide and empowers a global community affected by the second leading cause of blindness.

touchOPHTHALMOLOGY caught up with the President of the Glaucoma Research Foundation, Thomas Brunner, to discuss the objectives of the Foundation in 2022, research priorities and some exciting upcoming events.

For more information, please visit: https://glaucoma.org/

Questions:

  1. What are the objectives of the Glaucoma Research Foundation (GRF)? (00:22)
  2. What are the major challenges faced by the glaucoma community at the moment? (01:12)
  3. What are the GRF’s research priorities for the coming year? (02:26)

Disclosures: Thomas Brunner has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.

 

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup